Spinal cord intramedullary arteriovenous malformations (AVMs) pose a therapeutic challenge. Because of their complex angioanatomy, surgical excision of these lesions is difficult at best. Over the past decade, endovascular therapy has been established as an alternative treatment modality. As an embolic agent, N-butyl cyanoacrylate (NBCA) posed several problems such as difficulty of use and unpredictable performance. Onyx (ev3, Irvine, California, USA), an alternative liquid embolic agent, possesses several advantageous properties, such as increased control of agent delivery, over previous embolic agents like NBCA. However, reports of Onyx use in treating spinal intramedullary AVMs are still rare, especially in paediatric patients. We report a paediatric patient with glomus-type spinal intramedullary AVM treated successfully with Onyx with intermediate-term outcome.
- Arteriovenous malformation
- spinal cord
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.